Surgical Site Infections

2
Pipeline Programs
1
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ondine Biomedical
Ondine BiomedicalBC - Vancouver
3 programs
1
1
nasal antimicrobial photodisinfection therapyPhase 31 trial
methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activationPhase 21 trial
Nasal antimicrobial photodisinfection therapyN/A1 trial
Active Trials
NCT07189858RecruitingEst. Apr 2026
NCT05090657CompletedEst. Aug 2022
NCT06702878RecruitingEst. Apr 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Ondine Biomedicalnasal antimicrobial photodisinfection therapy
Ondine Biomedicalmethylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Ondine BiomedicalNasal antimicrobial photodisinfection therapy

Clinical Trials (3)

NCT06702878Ondine Biomedicalnasal antimicrobial photodisinfection therapy

Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections

Start: Dec 2024Est. completion: Apr 2026
Phase 3Recruiting
NCT05090657Ondine Biomedicalmethylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation

Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures

Start: Feb 2022Est. completion: Aug 2022
Phase 2Completed
NCT07189858Ondine BiomedicalNasal antimicrobial photodisinfection therapy

Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada

Start: Jan 2026Est. completion: Apr 2026
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials
1 companies competing in this space